Results 1 to 10 of about 983,540 (218)

Long-term safety and effectiveness of mRNA-1273 vaccine in adults: COVE trial open-label and booster phases [PDF]

Nature Communications
Primary vaccination with mRNA-1273 (100-µg) was safe and efficacious at preventing coronavirus disease 2019 (COVID-19) in the previously reported, blinded Part A of the phase 3 Coronavirus Efficacy (COVE; NCT04470427) trial in adults (≥18 years) across ...
Lindsey R. Baden, Hana M. El Sahly, Brandon Essink, Dean Follmann, Gregory Hachigian, Cynthia Strout, J. Scott Overcash, Susanne Doblecki-Lewis, Jennifer A. Whitaker, Evan J. Anderson, Kathleen Neuzil, Lawrence Corey, Frances Priddy, Joanne E. Tomassini, Mollie Brown, Bethany Girard, Dina Stolman, Veronica Urdaneta, Xiaowei Wang, Weiping Deng, Honghong Zhou, Avika Dixit, Rituparna Das, Jacqueline M. Miller, the COVE Trial Consortium   +24 more
doaj   +3 more sources

Anti-SARS-CoV-2 antibody dynamics after primary vaccination with two-dose inactivated whole-virus vaccine, heterologous mRNA-1273 vaccine booster, and Omicron breakthrough infection in Indonesian health care workers [PDF]

BMC Infectious Diseases
Background Data on the dynamics and persistence of humoral immunity against SARS-CoV-2 after primary vaccination with two-dose inactivated vaccine (CoronaVac) are limited.
Suwarti Suwarti, Gilbert Lazarus, Sabighoh Zanjabila, Robert Sinto, Fransiska Fransiska, Theresia Deborah, Dwi Oktavia, Junaidah Junaidah, Santayana Santayana, Henry Surendra, Jeng Yuliana, Herlina Pardosi, Nunung Nuraeni, Saraswati Soebianto, Novi Dwi Susilowati, Decy Subekti, Ariel Pradipta, J. Kevin Baird, Le Van Tan, Susanna Dunachie, Anuraj H. Shankar, Erni J. Nelwan, Raph L. Hamers, SEACOVARIANTS Consortium   +23 more
doaj   +3 more sources

Safety and durability of mRNA-1273–induced SARS-CoV-2 immune responses in adolescents: results from the phase 2/3 TeenCOVE trialResearch in context [PDF]

EClinicalMedicine
Summary: Background: Longitudinal changes in vaccination-induced immune response remain inadequately characterized in adolescents. We present long-term safety, immunogenicity, and COVID-19 incidence following a 2-dose mRNA-1273 100-μg primary series ...
Amparo L. Figueroa, Kashif Ali, Gary Berman, Honghong Zhou, Weiping Deng, Wenqin Xu, Stephanie Lussier, Bethany Girard, Frank J. Dutko, Karen Slobod, Anne Yeakey, Frances Priddy, Jacqueline M. Miller, Rituparna Das   +13 more
doaj   +2 more sources

Safety, Tolerability, and Immunogenicity of the Pneumococcal Vaccines PPSV23 or PCV15 Co-Administered with a Booster Dose of mRNA-1273 SARS-CoV-2 Vaccine in Healthy Adults ≥50 Years of Age [PDF]

Vaccines
Background/Objectives: Streptococcus pneumoniae with, or following, severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection has been associated with increased mortality, particularly in older adults.
Tosin Omole, Enrique Pelayo, Aaron S. Weinberg, Spyros Chalkias, Zelalem Endale, Gretchen Tamms, Tina M. Sterling, Lori Good, Tulin Shekar, Morgan Johnson, Natalie Banniettis, Ulrike K. Buchwald, Alejandra Esteves-Jaramillo   +12 more
doaj   +2 more sources

Immunogenicity of mRNA-1273 and BNT162b2 in Immunocompromised Patients: Systematic Review and Meta-analysis Using GRADE [PDF]

Infectious Diseases and Therapy
Introduction Immunocompromised (IC) patients mount poor immune responses to vaccination. Higher-dose coronavirus disease 2019 (COVID-19) vaccines may offer increased immunogenicity.
Sushma Kavikondala, Katrin Haeussler, Xuan Wang, Anne Spellman, Mary T. Bausch-Jurken, Pawana Sharma, Mohammadreza Amiri, Anna Krivelyova, Sonam Vats, Maria Nassim, Nitendra Kumar, Nicolas Van de Velde   +11 more
doaj   +2 more sources

Safety and Immunogenicity of the mRNA-1273 Coronavirus Disease 2019 Vaccine in Solid Organ Transplant Recipients. [PDF]

J Infect Dis
Figueroa AL, Azzi JR, Eghtesad B, Priddy F, Stolman D, Siangphoe U, Leony Lasso I, de Windt E, Girard B, Zhou H, Miller JM, Das R.   +11 more
europepmc   +3 more sources

Antibody Response in Immunocompromised Patients After the Administration of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Vaccine BNT162b2 or mRNA-1273: A Randomized Controlled Trial [PDF]

, 2022
BACKGROUND BNT162b2 by Pfizer-BioNTech and mRNA-1273 by Moderna are the most commonly used vaccines to prevent severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infections.
Abela, Irene A, Amico, Patrizia, Audigé, Annette, Braun, Dominique L, Briel, Matthias, Bucher, Heiner C, Chammartin, Frédérique, Eichenberger, Anna L, Günthard, Huldrych F, Hasse, Barbara, Koller, Michael T, Kusejko, Katharina, Mueller, Nicolas J, Müller, Thomas F, Rauch, Andri, Schuurmans, Macé M, Speich, Benjamin, Stoeckle, Marcel P, Tamm, Michael, Trkola, Alexandra   +19 more
core   +6 more sources

Comparative effectiveness of BNT162b2 versus mRNA-1273 covid-19 vaccine boosting in England: matched cohort study in OpenSAFELY-TPP [PDF]

, 2023
Objective To compare the effectiveness of the BNT162b2 mRNA (Pfizer-BioNTech) and mRNA-1273 (Moderna) covid-19 vaccines during the booster programme in England. Design Matched cohort study, emulating a comparative effectiveness trial.
Andrews, Colm D, Bacon, Sebastian CJ, Curtis, Helen J, Goldacre, Ben, Hernán, Miguel A, Horne, Elsie MF, Hulme, William J, Keogh, Ruth H, MacKenna, Brian, Mehrkar-Asl, Amir, Morley, Jessica, Palmer, Tom M, Parker, Edward PK, Sterne, Jonathan AC, Walker, Alex J, Walker, Venexia, Williamson, Elizabeth J   +16 more
core   +5 more sources

Determinants of protective humoral response to mRNA-1273 and BNT162b2 vaccines in peritoneal dialysis patients: a prospective cohort study. [PDF]

BMC Nephrol
Dimitrov Y, Krummel T, Chantrel F, Heibel F, Kribs M, Hannedouche T.   +5 more
europepmc   +3 more sources

Immunogenicity and safety of heterologous mRNA-1273/MVC-COV1901 vaccination versus homologous mRNA1273 vaccination: A randomized, double-blind controlled study

Journal of the Formosan Medical Association, 2023
Background/Purpose: MVC-COV1901 is a protein vaccine based on the same SARS-CoV-2 strain used in mRNA vaccine mRNA-1273. Data are lacking on immunogenicity and safety of MVC-COV1901 as heterologous boost for people already received one dose of mRNA-1273.
Szu-Ting Huang, Yu-Shan Huang, Wang-Da Liu, Sung-Ching Pan, Hsin-Yun Sun, Chia-En Lien, Charles Chen, Szu-Min Hsieh   +7 more
doaj   +1 more source